|
|
|
|
|
07.07.26 - 07:03
|
Roche presents new data in Alzheimer′s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC (GlobeNewswire EN)
|
|
|
Basel, 7 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data from its Alzheimer's disease portfolio at the Alzheimer's Association International Conference® 2026 (AAIC®) in London on 12-15 July. These data demonstrate how Roche is advancing the development of next-generation medicines and diagnostic tests, driven by a mission to slow, stop or even prevent the progression of Alzheimer's disease. In total, there are 18 oral and poster presentations. Highlights include five oral presentations as part of a trontinemab Featured Research Session, an oral Perspectives Session on neuroimmune targets such as NLRP3 for neurodegenerative diseases, and presentations on the use of Roche's Elecsys® pTau217 and pTau181 blood tests to support Alzheimer's disease diagnosis....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.07.26 - 10:48
|
European Champions: ASML, Novo und GSK sorgen für Schwung (Der Aktionaer)
|
|
|
In einer volatilen Börsenphase hat sich der European Champions Index sehr robust entwickelt und steht nun kurz vor einem neuen Allzeithoch. Wesentliche Erfolgsfaktoren sind die defensive Aufstellung und die Branchenstreuung. Mit Novo Nordisk, Novartis, Astrazeneca, GSK, Roche und Sanofi entfällt rund die Hälfte der Aktien auf den Gesundheitssektor....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.07.26 - 15:21
|
The European Investment Bank Grants Orano a Loan of €125 Million to Finance Orano Med′s Innovations and Industrial Infrastructure (Business Wire)
|
|
|
PARIS--(BUSINESS WIRE)--The European Investment Bank (EIB) and Orano announced today the signing of a €125 million credit line to finance the development of Orano Med and its industrial infrastructure, notably the construction of the Advanced Thorium Extraction Facility (ATEF), located in Bessines-sur-Gartempe, France.Orano Med, a subsidiary of the Orano group specializing in nuclear medicine, develops lead-212-based targeted alpha therapies, a new class of cancer treatments. By using the unique properties of alpha-emitter lead-212, these therapies aim at the targeted destruction of cancer cells, while limiting the impact on surrounding healthy tissue. Orano Med's clinical pipeline currently comprises four programs, run either independently or with its partners, evaluating these treatments across a wide range of cancer types that represent significant unmet medical needs. The company's partners include major pharmaceutical groups such as Sanofi and Roche, as well as Swiss biotech Molecular Partners.AT...
|
|
|
|
|
|
|
30.06.26 - 09:42
|
Roche Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Roche von 346 auf 348 Franken angehoben, aber die Einstufung auf "Neutral" belassen. Analyst James Quigley rechnet mit einem unschönen Halbjahresbericht der Schweizer, ......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
